This is a preview of subscription content, log in via an institution to check access.
References
Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991;42:321–8.
Besancon M, Simon A, Sachs G, Shin JM. Sites of action of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438–46.
Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebocontrolled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastric concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079–89.
Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, et al. Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. Aliment Pharmacol Ther 1998;12: 789–95.
Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz, Bell NE, Humphries TJ, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active duodenal ulcer-a European multicentre study. Aliment Pharmacol Ther 1999;13: 179–86.
Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. A double-blind, multicenter, European trial. Dig Dis Sci 2000;45:845–53.
Delchier JC, Cohen G, Humpries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. Scand J Gastroenterol 2000;35:1245–50.
Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:49–57.
Galmiche JP, Zerrib F, Ducrotte P, Fournet J, Rampal P, Avasthy N, et al. Decreasing oesophageal acid exposure in patinets with GERD: a comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 2001;15:1343–50.
Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27–36.
Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001;13:611–6.
Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001;13:S43–7.
Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Colling DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249–58.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sugano, K. Rabeprazole: quest for the best PPI. J Gastroenterol 37, 233–234 (2002). https://doi.org/10.1007/s005350200028
Published:
Issue Date:
DOI: https://doi.org/10.1007/s005350200028